KR20240145472A - 사트랄리주맙을 사용하는 자기면역 뇌염의 치료 - Google Patents

사트랄리주맙을 사용하는 자기면역 뇌염의 치료 Download PDF

Info

Publication number
KR20240145472A
KR20240145472A KR1020247027265A KR20247027265A KR20240145472A KR 20240145472 A KR20240145472 A KR 20240145472A KR 1020247027265 A KR1020247027265 A KR 1020247027265A KR 20247027265 A KR20247027265 A KR 20247027265A KR 20240145472 A KR20240145472 A KR 20240145472A
Authority
KR
South Korea
Prior art keywords
encephalitis
nmdar
subject
lgi1
satralizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027265A
Other languages
English (en)
Korean (ko)
Inventor
다카토시 오자와
히로아키 이다
하지메 이토
슌스케 요시다
šœ스케 요시다
질리안 스미스
시안 레논-크림스
가엘 클링겔슈미트
뷔딩겐 한스-크리스티안 폰
바우만 한나 실버
제임스 오버렐
샤밀라 라잔
Original Assignee
추가이 세이야쿠 가부시키가이샤
제넨테크, 인크.
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤, 제넨테크, 인크., 에프. 호프만-라 로슈 아게 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20240145472A publication Critical patent/KR20240145472A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247027265A 2022-01-19 2023-01-18 사트랄리주맙을 사용하는 자기면역 뇌염의 치료 Pending KR20240145472A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
US63/300,893 2022-01-19
PCT/JP2023/001270 WO2023140269A1 (en) 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with satralizumab

Publications (1)

Publication Number Publication Date
KR20240145472A true KR20240145472A (ko) 2024-10-07

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247027265A Pending KR20240145472A (ko) 2022-01-19 2023-01-18 사트랄리주맙을 사용하는 자기면역 뇌염의 치료

Country Status (11)

Country Link
US (1) US20250127891A1 (https=)
EP (1) EP4466018A4 (https=)
JP (1) JP2025502891A (https=)
KR (1) KR20240145472A (https=)
CN (1) CN118900699A (https=)
AU (1) AU2023209259A1 (https=)
CA (1) CA3243067A1 (https=)
IL (1) IL314213A (https=)
MX (1) MX2024008835A (https=)
TW (1) TW202337495A (https=)
WO (1) WO2023140269A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
WO2010035769A1 (ja) 2008-09-26 2010-04-01 中外製薬株式会社 改良された抗体分子
US20120039840A1 (en) 2008-12-02 2012-02-16 Hunter Christopher A Use of IL-27-P28 to antagonize IL-6 mediated signaling
WO2016136933A1 (ja) 2015-02-27 2016-09-01 中外製薬株式会社 Ｉｌ－６関連疾患治療用組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020202839A1 (https=) * 2019-03-29 2020-10-08

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
WO2010035769A1 (ja) 2008-09-26 2010-04-01 中外製薬株式会社 改良された抗体分子
US20120039840A1 (en) 2008-12-02 2012-02-16 Hunter Christopher A Use of IL-27-P28 to antagonize IL-6 mediated signaling
WO2016136933A1 (ja) 2015-02-27 2016-09-01 中外製薬株式会社 Ｉｌ－６関連疾患治療用組成物

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Abboud H, Probasco J, Irani SR, et al., J Neurol Neurosurg Psychiatry 2021. doi: 10.1136/jnnp-2020-325302
Dalmau J, Armangue T, Lancet Neurology 2019;11:1045-1057
Dubey D, Pittock S, Kelly C, et al., Ann Neurol 2018;83:166-77
Gadoth A, Pittock S, Dubey D, et al., Ann Neurol. 2017;82:79-92
Hang HL, Zhang JH, Chen DW, et al., Front Neurol 2020;11:852
Hughes EG, Peng X, Gleichman AJ, et al., J Neurosci 2010;30:5866-75
Leypoldt F, Wandinger K-P, Bien C, et al., Eur Neurol Rev 2013;8:31-7
Mikasova L, De Rossi P, Bouchet D, et al., Brain 2012;135:1606-21
Moscato EH, Peng X, Jain A, et al., Ann Neurol 2014;76:108-19
Ohkawa T, Fukata Y, Miwako Y, et al., J Neurosci 2013;33:18161-74
Petit-Pedrol M, Sell J, Planaguma J, et al., Brain 2018;141:3144-59
Rosch RE, Wright S, Cooray G, et al., Proc Natl Acad Sci USA 2018;115:E9916-25
van Sonderen A, Thijs R, Coenders E, et al., Neurology 2016;87:1449-56
Venkatesan A, Tunkel AR, Bloch KC, et al., Clin Infect Dis 2013;57:1114-28

Also Published As

Publication number Publication date
TW202337495A (zh) 2023-10-01
EP4466018A4 (en) 2026-03-25
MX2024008835A (es) 2024-07-25
CA3243067A1 (en) 2023-07-27
CN118900699A (zh) 2024-11-05
IL314213A (en) 2024-09-01
AU2023209259A1 (en) 2024-07-18
JP2025502891A (ja) 2025-01-28
WO2023140269A1 (en) 2023-07-27
EP4466018A1 (en) 2024-11-27
US20250127891A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
WO2023140269A1 (en) Treatment of autoimmune encephalitis with satralizumab
Oaklander et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews
Vergunst et al. Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial
Glaubitz et al. New insights into the treatment of myositis
AU2008212004B2 (en) Method for the treatment of multiple sclerosis
US20250034265A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
Gerischer et al. New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making: L. Gerischer et al.
US20220396630A1 (en) Type i interferon inhibition in systemic lupus erythematosus
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
HK40111127A (zh) 使用萨特利珠单抗治疗自身免疫性脑炎
EP4370547A1 (en) Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
HK40080317A (en) Type i interferon inhibition in systemic lupus erythematosus
HK40080317B (en) Type i interferon inhibition in systemic lupus erythematosus
Goodfellow et al. 2016 Inflammatory Neuropathy Consortium and ‘GBS 100’Centenary Symposium and Ceilidh
Oaklander Review type: Overview Review number: 178
HK1157192B (en) Method for the treatment of multiple sclerosis
HK1157192A (en) Method for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240814

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application